A phase II multi‐institutional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐fluorouracil as a short‐term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study

Louise M. Morrell, Ardalan Bach, Stephen P. Richman, Phyllis Goodman, Thomas R. Fleming, John S. Macdonald

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5%. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.

Original languageEnglish (US)
Pages (from-to)363-366
Number of pages4
JournalCancer
Volume67
Issue number2
DOIs
StatePublished - Jan 15 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II multi‐institutional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐fluorouracil as a short‐term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this